Rodriguez-TorresMaribel MR, Rodriguez-OrengoJose JR, Rios-BedoyaCarlos CR; International Conference on AIDS.

Int Conf AIDS. 2002 Jul 7-12; 14: abstract no. WePeB6043.

Fundacion De Investigacion De Diego, Santurce, Puerto Rico

BACKGROUND: HIV/HCV co-infection is associated with higher progression to liver cirrhosis. A significant number of patients will not achive SVR with INF therapy. The effect of INF therapy in liver histology in this population is unknown. METHODS: We evaluated 33 patients with pre-and post-INF Tx. liver biopsies. History was assessed: age, gender, risk factors, alcohol use, HIV Tx., duration of HCV. Labs tests were obtained at both time points. 24 patients (73%) received INF Tx. Analysis of Ishak score was done. Fibrosis score (0-5), activity score (0-18), fibrosis progression rate and necrosis progression rate were calculated. Mean duration of INF Tx. was 11.5 months. Fisher's p-value and Paired t-tests was used to compare variables. RESULTS: Most patients were male (82%), with a mean age of 42.2 years, HCV Gen 1(75.8%).Most patients (67%) were in HAART with mean CD4 of 478 cells/mm3. Mean HIV PCR is 2.5 log and 19% were HIV PCR non-detectable. Mean HCV PCR was 5.9 log and 54% had as risk factor IVDU. Mean fibrosis score at the first biopsy(FS1) was 2.78 vs. 3.47 at the 2nd biopsy(P=<.05). The necrosis score(NS1) was significantly reduced from the 1st biopsy with a mean score of 7.94 vs. NS2 of 5.97(P=<.005). In addition the necrosis progression rate, NPR1 was reversed, between the two biopsies(NPR1=0.48 vs. NPR2= -0.72, P=<.01).INF Tx. vs. non-Tx. analysis show: FPR1 is .149(N=20) vs. 0.27(N=5). The FPR2 is 0.180 and 24 respectively. The difference between FPR2 and FPR1 is .4685(N=5) vs -0.6982(N=20) for the INF treated group. This difference is not significant. CONCLUSION: INF Tx. in co infected non-responders has a significant effect in activity improvement. No conclusion can be reached in this population,at this moment,regarding fibrosis progression,but this data suggests that fibrosis progression can be diminished or stopped with IFN Tx. Further follow up with liver histology is needed to assess the long-term impact of Tx.

Publication Types:

• Meeting Abstracts

Keywords:

• Acquired Immunodeficiency Syndrome
• Antiretroviral Therapy, Highly Active
• Disease Progression
• Fibrosis
• HIV Infections
• HIV Seropositivity
• Hepacivirus
• Humans
• Liver
• Liver Cirrhosis
• Male
• Risk Factors
• drug therapy
• therapy

Other ID:

• GWAIDS0020282

UI: 102259319

From Meeting Abstracts